Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 16/20 | 0.61 |
| ▸ | CA1 | P00915 | 9/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11001503 | 0.83 | CA2 (0.63) | CA2CA1CA12CA9 | |
| SCHEMBL16263697 | 0.82 | UNG (0.53) | CA2CA1CA12CA9 | |
| SCHEMBL2791574 | 0.81 | CA2 (0.66) | CA2CA1CA12CA9DGAT1 | |
| SCHEMBL2792747 | 0.81 | CA2 (0.66) | CA2CA1CA12CA9DGAT1 | |
| SCHEMBL9943491 | 0.81 | CA2 (0.66) | CA2CA1CA12CA9DGAT1 | |
| SCHEMBL15156311 | 0.81 | CYP26A1 (0.46) | CA2CA1CA12CA9ALDH1A1 | |
| SCHEMBL12982952 | 0.80 | CA2 (0.65) | CA2CA1CA12CA9ALDH1A1 | |
| SCHEMBL7823240 | 0.80 | CA2 (0.65) | CA2CA1CA12CA9ALDH1A1 | |
| SCHEMBL21639043 | 0.80 | CA2 (0.65) | CA2CA1CA12CA9ALDH1A1 | |
| SCHEMBL21639045 | 0.80 | CA2 (0.65) | CA2CA1CA12CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238656-B2 | Imidazo[4,5-b]pyridine derivatives as ALK and JAK modulators for the treatment of proliferative disorders | CEPHALON, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-9238656-B2 | Imidazo[4,5-b]pyridine derivatives as ALK and JAK modulators for the treatment of proliferative disorders | CEPHALON, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20140350011-A1 | Imidazo[4,5-b]pyridine Derivatives as ALK and JAK Modulators for the Treatment of Proliferative Disorders | CEPHALON, INC. | 2014-11-27 | — | — | US | disclosed |
| US-20140350011-A1 | Imidazo[4,5-b]pyridine Derivatives as ALK and JAK Modulators for the Treatment of Proliferative Disorders | CEPHALON, INC. | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350011-A1 | Imidazo[4,5-b]pyridine Derivatives as ALK and JAK Modulators for the Treatment of Proliferative Disorders | JAK1, ALK, JAK2 | CA2 3486/4885CA1 4873/4885CA12 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.